Neochromosome
Private Company
Total funding raised: $35M
Overview
Neochromosome is a San Diego-based biotech firm leveraging its first-in-class platform for designing, building, and testing synthetic eukaryotic genomes. Founded in 2014 and now a subsidiary of Opentrons Labworks, it offers services ranging from complex DNA synthesis to full chromosome assembly and delivery. The company targets partners in therapeutics and industrial biotechnology, aiming to enable cell-based manufacturing with custom-designed genomes.
Technology Platform
A vertically integrated platform for genome-scale engineering, including highly automated complex DNA synthesis, locus-scale genome rewriting/verification, and de novo design, synthesis, and delivery of entire chromosomes. Leverages robotics from parent company Opentrons for a scalable 'genome foundry'.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Neochromosome competes with large DNA synthesis providers (e.g., Twist Bioscience) and gene editing firms, but its differentiation lies in the scale and integration of its platform for full chromosome design and assembly. It occupies a specialized niche between traditional gene synthesis and whole-genome engineering.